NCT04789668 2026-03-18
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
81 trialsNCT02565433 2026-03-16
PRAMECE
Centre Oscar Lambret
Phase NA Terminated
NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
NCT02780128 2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1 Terminated
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT06315296 2026-03-03
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
Thomas Jefferson University
Phase NA Terminated
NCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04187404 2026-01-30
Spencer
Enterome
Phase 1/2 Terminated
NCT03334305 2026-01-29
ACTION
University of Florida
Phase 1 Terminated
NCT04825275 2026-01-23
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
Milton S. Hershey Medical Center
Phase EARLY_PHASE1 Terminated
NCT05746481 2026-01-22
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT06193174 2026-01-22
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
University of Alabama at Birmingham
Phase 1 Terminated
NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
NCT04869449 2026-01-07
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
Milton S. Hershey Medical Center
Phase EARLY_PHASE1 Terminated
NCT04113408 2026-01-06
MENTHE
Fondation Ophtalmologique Adolphe de Rothschild
Terminated
NCT05553522 2025-12-31
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Baptist Health South Florida
Phase 1 Terminated
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT06359379 2025-12-18
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Shuttle Pharmaceuticals, Inc.
Phase 2 Terminated
NCT06098248 2025-12-15
cCeLLExvivo
VPIX Medical
Phase NA Terminated
NCT04955743 2025-11-24
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT03107780 2025-11-13
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT03904862 2025-10-30
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
Pediatric Brain Tumor Consortium
Phase 1/2 Terminated
NCT03396575 2025-10-29
BRAVO
University of Florida
Phase 1 Terminated
NCT04424966 2025-10-24
Infigratinib in Recurrent High-Grade Glioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Terminated
NCT04402073 2025-10-23
PersoMed-I
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03868943 2025-10-21
JAZZ
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00897286 2025-10-20
Study of Stored Tumor Samples in Young Patients With Brain Tumors
St. Jude Children's Research Hospital
Terminated
NCT04982926 2025-10-14
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
Phase 1 Terminated
NCT04712721 2025-10-10
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
Novartis
Phase EARLY_PHASE1 Terminated
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT05130866 2025-10-07
POPLAR-NF2
Recursion Pharmaceuticals Inc.
Phase 2/3 Terminated
NCT05189366 2025-10-07
SOPHNEURO
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT04985604 2025-10-02
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 2 Terminated
NCT06270082 2025-09-19
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Ikena Oncology
Phase 1 Terminated
NCT04023331 2025-09-16
67Cu-SARTATEâ„¢ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
Clarity Pharmaceuticals Ltd
Phase 1/2 Terminated
NCT04762602 2025-09-16
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Hutchmed
Phase 1 Terminated
NCT01849952 2025-09-15
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Dartmouth-Hitchcock Medical Center
Terminated
NCT04462419 2025-09-10
18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain
Mayo Clinic
Terminated
NCT03347617 2025-09-09
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03149575 2025-09-04
STAR-3
Kintara Therapeutics, Inc.
Phase 3 Terminated
NCT05388877 2025-08-19
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Mayo Clinic
Phase 1 Terminated
NCT04074785 2025-08-17
SCCC-06319
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Terminated
NCT07121829 2025-08-14
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 1 Terminated
NCT03330197 2025-08-12
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Alaunos Therapeutics
Phase 1/2 Terminated